These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 32083571)
1. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations. Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571 [TBL] [Abstract][Full Text] [Related]
2. Establishment and validation of an immune-associated signature in lung adenocarcinoma. Wang Z; Chen X Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112 [TBL] [Abstract][Full Text] [Related]
3. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma. Zou X; Hu Z; Huang C; Chang J Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949 [TBL] [Abstract][Full Text] [Related]
4. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma. Zengin T; Önal-Süzek T BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690 [TBL] [Abstract][Full Text] [Related]
5. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies. Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089 [TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988 [TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases]. Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780 [No Abstract] [Full Text] [Related]
8. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma. Jiang H; Xu S; Chen C BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300 [TBL] [Abstract][Full Text] [Related]
9. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features. Yu J; Hu Y; Xu Y; Wang J; Kuang J; Zhang W; Shao J; Guo D; Wang Y BMC Cancer; 2019 Mar; 19(1):263. PubMed ID: 30902072 [TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival. Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632 [TBL] [Abstract][Full Text] [Related]
11. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma. Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701 [TBL] [Abstract][Full Text] [Related]
12. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis. Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191 [No Abstract] [Full Text] [Related]
13. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model. Sun N; Chu J; Hu W; Chen X; Yi N; Shen Y Sci Rep; 2022 Jan; 12(1):27. PubMed ID: 34996932 [TBL] [Abstract][Full Text] [Related]
14. Survival prediction model for non-small cell lung cancer based on somatic mutations. Zhang W; Lin X; Li X; Wang M; Sun W; Han X; Sun D J Gene Med; 2020 Sep; 22(9):e3206. PubMed ID: 32367667 [TBL] [Abstract][Full Text] [Related]
15. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma. Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484 [TBL] [Abstract][Full Text] [Related]
16. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184 [TBL] [Abstract][Full Text] [Related]
17. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma. Dong M; Yang Z; Li X; Zhang Z; Yin A Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775 [TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas. Bian Y; Sui Q; Bi G; Zheng Y; Zhao M; Yao G; Xue L; Zhang Y; Fan H Dis Markers; 2021; 2021():3219594. PubMed ID: 34721732 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298 [TBL] [Abstract][Full Text] [Related]
20. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma. Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]